RhumbLine Advisers’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $113M | Sell |
2,641,843
-32,798
| -1% | -$1.78M | 0.09% | 197 |
|
|
2026
Q1 | $168M | Sell |
2,674,641
-22,884
| -0.8% | -$1.83M | 0.14% | 114 |
|
|
2025
Q4 | $257M | Sell |
2,697,525
-28,768
| -1% | -$2.82M | 0.21% | 79 |
|
|
2025
Q3 | $266M | Sell |
2,726,293
-11,332
| -0.4% | -$1.17M | 0.21% | 75 |
|
|
2025
Q2 | $294M | Sell |
2,737,625
-58,819
| -2% | -$5.95M | 0.25% | 59 |
|
|
2025
Q1 | $282M | Buy |
2,796,444
+55,006
| +2% | +$5.54M | 0.26% | 60 |
|
|
2024
Q4 | $245M | Sell |
2,741,438
-113,403
| -4% | -$9.98M | 0.22% | 72 |
|
|
2024
Q3 | $239M | Sell |
2,854,841
-104,581
| -4% | -$8.24M | 0.22% | 75 |
|
|
2024
Q2 | $228M | Sell |
2,959,422
-11,466
| -0.4% | -$839K | 0.21% | 78 |
|
|
2024
Q1 | $203M | Buy |
2,970,888
+14,602
| +0.5% | +$939K | 0.2% | 93 |
|
|
2023
Q4 | $171M | Buy |
2,956,286
+8,634
| +0.3% | +$461K | 0.18% | 100 |
|
|
2023
Q3 | $156M | Buy |
2,947,652
+24,133
| +0.8% | +$1.27M | 0.18% | 97 |
|
|
2023
Q2 | $158M | Buy |
2,923,519
+15,558
| +0.5% | +$813K | 0.18% | 95 |
|
|
2023
Q1 | $145M | Sell |
2,907,961
-17,212
| -0.6% | -$811K | 0.18% | 100 |
|
|
2022
Q4 | $135M | Buy |
2,925,173
+194,639
| +7% | +$8.43M | 0.18% | 108 |
|
|
2022
Q3 | $106M | Buy |
2,730,534
+66,703
| +3% | +$2.68M | 0.16% | 114 |
|
|
2022
Q2 | $99.3M | Buy |
2,663,831
+98,798
| +4% | +$4.02M | 0.14% | 129 |
|
|
2022
Q1 | $114M | Buy |
2,565,033
+76,742
| +3% | +$3.33M | 0.15% | 122 |
|
|
2021
Q4 | $106M | Buy |
2,488,291
+17,546
| +0.7% | +$737K | 0.13% | 132 |
|
|
2021
Q3 | $107M | Sell |
2,470,745
-79,749
| -3% | -$3.53M | 0.15% | 122 |
|
|
2021
Q2 | $109M | Sell |
2,550,494
-124,331
| -5% | -$5.23M | 0.14% | 125 |
|
|
2021
Q1 | $103M | Sell |
2,674,825
-183,581
| -6% | -$6.95M | 0.14% | 129 |
|
|
2020
Q4 | $103M | Buy |
2,858,406
+57,397
| +2% | +$2.07M | 0.14% | 131 |
|
|
2020
Q3 | $107M | Sell |
2,801,009
-9,130
| -0.3% | -$352K | 0.17% | 114 |
|
|
2020
Q2 | $98.7M | Buy |
2,810,139
+65,962
| +2% | +$2.38M | 0.16% | 119 |
|
|
2020
Q1 | $89.5M | Buy |
2,744,177
+85,952
| +3% | +$3.36M | 0.19% | 104 |
|
|
2019
Q4 | $120M | Buy |
2,658,225
+23,480
| +0.9% | +$982K | 0.2% | 96 |
|
|
2019
Q3 | $107M | Buy |
2,634,745
+60,662
| +2% | +$2.57M | 0.2% | 97 |
|
|
2019
Q2 | $111M | Sell |
2,574,083
-25,013
| -1% | -$962K | 0.21% | 88 |
|
|
2019
Q1 | $99.8M | Buy |
2,599,096
+100,341
| +4% | +$3.83M | 0.19% | 97 |
|
|
2018
Q4 | $88.3M | Buy |
2,498,755
+48,890
| +2% | +$1.77M | 0.19% | 99 |
|
|
2018
Q3 | $94.3M | Sell |
2,449,865
-35,756
| -1% | -$1.25M | 0.18% | 110 |
|
|
2018
Q2 | $81.3M | Buy |
2,485,621
+87,665
| +4% | +$2.64M | 0.16% | 123 |
|
|
2018
Q1 | $65.5M | Sell |
2,397,956
-26,344
| -1% | -$716K | 0.14% | 154 |
|
|
2017
Q4 | $60.1M | Buy |
2,424,300
+54,174
| +2% | +$1.49M | 0.12% | 172 |
|
|
2017
Q3 | $69.1M | Buy |
2,370,126
+56,189
| +2% | +$1.55M | 0.15% | 137 |
|
|
2017
Q2 | $64.1M | Buy |
2,313,937
+42,418
| +2% | +$1.13M | 0.15% | 143 |
|
|
2017
Q1 | $56.5M | Buy |
2,271,519
+47,510
| +2% | +$1.16M | 0.13% | 159 |
|
|
2016
Q4 | $48.1M | Buy |
2,224,009
+71,233
| +3% | +$1.55M | 0.12% | 176 |
|
|
2016
Q3 | $51.2M | Buy |
2,152,776
+98,764
| +5% | +$2.36M | 0.14% | 144 |
|
|
2016
Q2 | $48M | Buy |
2,054,012
+148,065
| +8% | +$3.2M | 0.14% | 140 |
|
|
2016
Q1 | $35.9M | Buy |
1,905,947
+70,513
| +4% | +$1.24M | 0.11% | 185 |
|
|
2015
Q4 | $33.8M | Sell |
1,835,434
-1,549
| -0.1% | -$27.8K | 0.11% | 186 |
|
|
2015
Q3 | $30.1M | Buy |
1,836,983
+45,882
| +3% | +$784K | 0.1% | 202 |
|
|
2015
Q2 | $31.7M | Buy |
1,791,101
+50,996
| +3% | +$911K | 0.1% | 207 |
|
|
2015
Q1 | $30.9M | Sell |
1,740,105
-24,639
| -1% | -$389K | 0.09% | 212 |
|
|
2014
Q4 | $23.4M | Sell |
1,764,744
-18,024
| -1% | -$230K | 0.07% | 265 |
|
|
2014
Q3 | $21.1M | Sell |
1,782,768
-64,228
| -3% | -$809K | 0.06% | 272 |
|
|
2014
Q2 | $23.6M | Sell |
1,846,996
-44,436
| -2% | -$578K | 0.07% | 263 |
|
|
2014
Q1 | $25.6M | Sell |
1,891,432
-63,660
| -3% | -$836K | 0.08% | 244 |
|
|
2013
Q4 | $23.5M | Sell |
1,955,092
-92,663
| -5% | -$1.09M | 0.07% | 266 |
|
|
2013
Q3 | $24M | Buy |
2,047,755
+67,017
| +3% | +$725K | 0.07% | 259 |
|
|
2013
Q2 | $18.4M | Buy |
+1,980,738
| New | +$16.8M | 0.06% | 306 |
|
Other funds holding BSX
VCM
VPM
BG
RhumbLine Advisers's BSX Position: Q2 2026 in Review
RhumbLine Advisers reduced its Boston Scientific (BSX) stake by 1.2% in Q2 2026, selling an estimated $1.78M and leaving 2,641,843 shares worth $113M. The position accounts for 0.09% of the portfolio, ranked #197.
RhumbLine Advisers first reported a position in BSX in Q2 2013 and has held it in 53 quarters since. The position peaked at $294M in Q2 2025. 1,162 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- RhumbLine Advisers held 2,641,843 shares of Boston Scientific worth $113M as of Q2 2026.
- RhumbLine Advisers sold 32,798 Boston Scientific shares in Q2 2026, an estimated $1.78M.
- Boston Scientific made up 0.09% of RhumbLine Advisers's portfolio in Q2 2026, its #197 holding.
- RhumbLine Advisers first reported a position in Boston Scientific in Q2 2013 and has held it in 53 quarters since.
- RhumbLine Advisers's Boston Scientific position peaked at $294M in Q2 2025.
- 1,162 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.